DA-5221-T(DA-5221-T) - 药物靶点：SGLT2_在研适应症：2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DA-5221-T

靶点

SGLT2

作用方式

抑制剂

作用机制

SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病

非在研适应症-

原研机构

Dong-A ST Co., Ltd.

在研机构

Dong-A ST Co., Ltd.

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 DA-5221-T 相关的临床试验

NCT06616883

/ Not yet recruiting临床1期

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over Study to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Single Administration of DA-5221_01 and Concomitant Administration of DA-5221_01-R1 and DA-5221_01-R2 Under Fasting Conditions in Healthy Adult Volunteers

Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers

开始日期2024-09-30

申办/合作机构

Dong-A ST Co., Ltd.

NCT06290349

/ Not yet recruiting临床3期

A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose control. The study focuses on assessing the effectiveness and safety of the triple combination therapy.

开始日期2024-02-28

申办/合作机构

Dong-A ST Co., Ltd.

100 项与 DA-5221-T 相关的临床结果

登录后查看更多信息

100 项与 DA-5221-T 相关的转化医学

登录后查看更多信息

100 项与 DA-5221-T 相关的专利（医药）

登录后查看更多信息

100 项与 DA-5221-T 相关的药物交易

登录后查看更多信息